LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Barasertib | 0.04 | uM | LJP5 | 72 | hr | 868 | 1420 | 3410 | 0.4166 | 0.2829 |
MDA-MB-231 | Barasertib | 0.12 | uM | LJP5 | 72 | hr | 868 | 1279 | 3410 | 0.3758 | 0.2173 |
MDA-MB-231 | Barasertib | 0.37 | uM | LJP5 | 72 | hr | 868 | 1244 | 3410 | 0.3654 | 0.2006 |
MDA-MB-231 | Barasertib | 1.11 | uM | LJP5 | 72 | hr | 868 | 1221 | 3410 | 0.3589 | 0.1892 |
MDA-MB-231 | Barasertib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1209 | 3410 | 0.3553 | 0.1832 |
MDA-MB-231 | Barasertib | 10 | uM | LJP5 | 72 | hr | 868 | 1246 | 3410 | 0.3656 | 0.2011 |
MDA-MB-231 | Vemurafenib | 0.04 | uM | LJP5 | 72 | hr | 868 | 3240 | 3410 | 0.9507 | 0.9486 |
MDA-MB-231 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 868 | 3233 | 3410 | 0.9475 | 0.9447 |
MDA-MB-231 | Vemurafenib | 0.37 | uM | LJP5 | 72 | hr | 868 | 3247 | 3410 | 0.9525 | 0.9515 |
MDA-MB-231 | Vemurafenib | 1.11 | uM | LJP5 | 72 | hr | 868 | 2853 | 3410 | 0.8377 | 0.8272 |
MDA-MB-231 | Vemurafenib | 3.33 | uM | LJP5 | 72 | hr | 868 | 2762 | 3410 | 0.8105 | 0.7982 |
MDA-MB-231 | Vemurafenib | 10 | uM | LJP5 | 72 | hr | 868 | 1762 | 3410 | 0.5167 | 0.4310 |
MDA-MB-231 | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 868 | 3487 | 3410 | 1.0230 | 1.0218 |
MDA-MB-231 | Enzastaurin | 0.12 | uM | LJP5 | 72 | hr | 868 | 3419 | 3410 | 1.0028 | 1.0023 |
MDA-MB-231 | Enzastaurin | 0.37 | uM | LJP5 | 72 | hr | 868 | 3475 | 3410 | 1.0207 | 1.0207 |
MDA-MB-231 | Enzastaurin | 1.11 | uM | LJP5 | 72 | hr | 868 | 3538 | 3410 | 1.0392 | 1.0393 |
MDA-MB-231 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 868 | 3483 | 3410 | 1.0229 | 1.0222 |
MDA-MB-231 | Enzastaurin | 10 | uM | LJP5 | 72 | hr | 868 | 3263 | 3410 | 0.9573 | 0.9565 |
MDA-MB-231 | Palbociclib | 0.04 | uM | LJP6 | 72 | hr | 868 | 2707 | 3556 | 0.7615 | 0.7494 |
MDA-MB-231 | Palbociclib | 0.12 | uM | LJP6 | 72 | hr | 868 | 2338 | 3556 | 0.6583 | 0.6279 |
MDA-MB-231 | Palbociclib | 0.37 | uM | LJP6 | 72 | hr | 868 | 1974 | 3556 | 0.5565 | 0.4987 |
MDA-MB-231 | Palbociclib | 1.11 | uM | LJP6 | 72 | hr | 868 | 1681 | 3556 | 0.4734 | 0.3845 |
MDA-MB-231 | Palbociclib | 3.33 | uM | LJP6 | 72 | hr | 868 | 1584 | 3556 | 0.4463 | 0.3439 |
MDA-MB-231 | Palbociclib | 10 | uM | LJP6 | 72 | hr | 868 | 1490 | 3556 | 0.4193 | 0.3043 |
MDA-MB-231 | PF562271 | 0.04 | uM | LJP6 | 72 | hr | 868 | 3236 | 3556 | 0.9117 | 0.9110 |